FARMINGDALE, N.Y., June 2, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today released its newly-developed 25mm BoneScalpel blade.
The new 25mm BoneScalpel blade now offers surgeons the tool to access previously unreachable anatomy as well as facilitates the cutting and removal of larger boney structures. “We are excited to add this new blade to our portfolio of solutions for the BoneScalpel system,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “We specifically developed the new 25mm blade in response to our surgeon customers needs to enable the completion of procedures not previously possible. We continue to work with leading surgeons from around the world to identify new opportunities to further expand the clinical utility of BoneScalpel.”
The BoneScalpel is an ultrasonic bone-cutting instrument that provides surgeons a clean, controlled bone incision and removal that is also soft-tissue sparing. “I have used the BoneScalpel extensively over the past several years and I view this technology as a vital piece of equipment for both standard laminectomies and more extensive osteotomies,” said Dr. Paul J. Holman, Director, Neurosurgical Spine Center, Houston Methodist Department of Neurosurgery, Houston, TX. “The BoneScalpel allows for rapid, safe removal of bone with a reduction in bleeding.”
Dr. Holman continued, “The new 25mm blade is an important addition to the choice of available tips. The extra length allows me to use the BoneScalpel for rapid bone removal during complex procedures such as pedicle subtraction osteotomies and vertebrectomies. The amount of local bone that is retained for fusion by using the BoneScalpel is also quite remarkable.”
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Corporate Contact | Investor Contact: |
Richard Zaremba - CFO | Joe Diaz |
Misonix, Inc. | Lytham Partners, LLC |
631-694-9555 | 602-889-9700 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/misonix-introduces-the-new-25-millimeter-blade-to-the-bonescalpel-portfolio-300092284.html
SOURCE Misonix, Inc.
Help employers find you! Check out all the jobs and post your resume.
